Basket | Login | Register

 
 
 
 

Why PharmaCog?

PharmaCog

Pharmacog Logo

The impact of Alzheimer’s disease in Europe

  • Alzheimer’s Disease is a complex disease which destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life.
  • Today approximately 26 million people sufferer world-wide. 2025 : the percentage of over-65s will raise from 15.4% of the EU population to 22.4% which will correlate with a rise in Alzheimer’s Disease
  • There are very few effective treatments currently available: those that are available only treat the symptoms, but not the underlying disease

The Challenges for new drug development in Alzheimer’s Disease

  • Alzheimer’s Disease is very complex
  • There are no validated models available which allow scientists to mimic the disease in the laboratory
  • The lack of ability to model disease means that it is difficult for drug developers to predict the best new medicines
  • There are no sensitive measures available that can be used to determine the effect of a new drug in small numbers of patients over a short period of time
  • Currently trials in Alzheimer’s disease need to run for 2 years and cost 10’s of millions Euros per study to test new medicines

 

 
 

Last Updated: Tuesday 13 March 2012

 

 
  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations
 
 

Options

  • Send this page to a friend